Cipher Pharmaceuticals Correlations
| CPH Stock | CAD 14.66 -0.15 -1.01% |
The current 90-days correlation between Cipher Pharmaceuticals and Canopy Growth Corp is -0.17 (i.e., Good diversification).Understanding Cipher Pharmaceuticals's correlation with other assets helps investors build better-diversified portfolios. When two assets are highly correlated, they tend to rise and fall together, reducing the benefit of holding both.
Cipher Pharmaceuticals Market Correlation
Average diversification
Across the chosen horizon, CPH and DJI show a correlation of 0.16 and fall into the Average diversification bucket. In portfolio terms, the overlap visualization shows how much shared movement remains after both positions are combined.
Cipher |
Correlation analysis helps compare Cipher Pharmaceuticals with similar exposures for allocation context. Where wash sale rules apply, substantially identical replacements can be restricted; this view is informational context only.
Moving against Cipher Stock
Related Correlations Analysis
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Cipher Stock performing well and Cipher Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Cipher Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| WEED | 3.80 | 0.04 | 0.02 | -0.06 | 4.23 | 6.62 | 65.32 | |||
| OGI | 2.80 | -0.20 | 0.00 | 0.54 | 0.00 | 6.10 | 29.72 | |||
| TSND | 7.78 | 0.94 | 0.09 | -0.86 | 9.12 | 18.18 | 121.97 | |||
| ACB | 2.64 | -0.34 | 0.00 | -0.63 | 0.00 | 5.75 | 30.59 | |||
| EDT | 1.74 | 0.08 | 0.04 | -11.86 | 1.88 | 3.94 | 15.23 | |||
| NGEN | 3.00 | -0.09 | 0.00 | -0.08 | 0.00 | 6.54 | 19.67 | |||
| HITI | 2.00 | -0.11 | 0.00 | -0.16 | 0.00 | 3.85 | 19.30 | |||
| GUD | 1.05 | 0.06 | 0.05 | 0.16 | 1.14 | 1.90 | 8.61 | |||
| FRX | 1.61 | -0.09 | 0.00 | 9.72 | 0.00 | 4.62 | 22.70 |
Be your own money manager
Optimization tools can help investors judge whether capital allocated to Cipher Pharmaceuticals is being used efficiently relative to other opportunities in the same equity universe. This is most useful when investors want to improve risk-adjusted return instead of simply owning more ideas at once.
Did you try this?
Run ETFs Now
ETFsFind actively traded Exchange Traded Funds (ETF) from around the world |
| All Next | Launch Module |
Cipher Pharmaceuticals Corporate Management
Governance review matters for Cipher Pharmaceuticals because boards and executives shape oversight, strategic discipline, and how shareholder interests are represented. This becomes more valuable when investors want to compare oversight quality across firms that may otherwise look financially similar.
| Hamed Ghanei | Chief Officer | Profile | |
| Ryan Mailling | Chief Officer | Profile | |
| Bryan Jacobs | Chief Officer | Profile | |
| Diane Gajewczyk | Vice Affairs | Profile | |
| Chuoru Li | Co Controller | Profile |